FAQ: What should clinicians know about congenital measles?

The American Academy of Pediatrics (AAP) has released new guidance in Red Book Online on congenital measles, developed in response to ongoing US measles outbreaks and a resulting increase in congenital measles cases nationwide. The resource, published September 8, 2026, addresses how congenital measles is defined, how it presents, how affected neonates should be evaluated and managed, infection prevention and control, long-term follow-up, and prevention.

Where published evidence exists, the recommendations are supported by references; where data are limited, the guidance reflects the opinion of experts in infectious diseases, public health, infection prevention and control, and fetal and newborn medicine. A central organizing principle is timing: management differs for neonates born after maternal prodromal symptom onset through 14 days after maternal rash onset vs those born more than 14 days after maternal rash onset.

What defines congenital measles, and how does it differ from neonatal measles?

Congenital measles refers to clinical and/or laboratory evidence of measles infection in a neonate within the first 10 days of life following intrauterine exposure. The fetus acquires the virus across the placenta during maternal viremia. Neonatal measles, by contrast, results from horizontal transmission after birth through close contact with an infectious person. Rash appearing more than 10 days after birth points to postnatal exposure.

Congenital measles appears to have been uncommon before vaccination, when most pregnant women had already been infected in childhood. In the measles elimination era, however, multiple case reports describe congenital measles among neonates whose birth parents lacked immunity before pregnancy and developed acute measles near delivery.

How often is maternal measles transmitted to the fetus, and what are the risks?

Transmission data are limited. Historical reports place the vertical transmission rate at approximately 25% to 30% when the birth parent develops measles in the days before delivery. More recently, 1 Canadian province identified 9 congenital measles cases among 51 confirmed measles infections during pregnancy in 2024 to 2025.

The most common fetal complications of maternal measles are pregnancy loss, premature delivery, and low birth weight. Before immune globulin was available, mortality attributable to congenital measles was reported to be as high as 30%. Affected neonates are also at increased risk of subacute sclerosing panencephalitis (SSPE), potentially with a shorter latency (months to a few years) between acute infection and onset than in older children. Available evidence does not support a link between measles in pregnancy and congenital defects.

What does congenital measles look like in a newborn?

Presentation varies widely, from no symptoms to the classic measles rash to fulminant multisystem disease and death. Fever, rash, and jaundice are common. The characteristic maculopapular eruption may be atypical, delayed, or absent, which the guidance attributes to the neonate's immature adaptive immune response, attenuation by passively acquired maternal antibodies, or possibly other factors. Thrombocytopenia, pneumonia, and neurologic complications can also occur.

Some neonates with congenital measles, including some who received immune globulin at birth, remain asymptomatic even though measles virus is detected.

Which neonates should be considered exposed, and why does the 14-day window matter?

Every neonate whose birth parent had measles during pregnancy should be considered exposed, regardless of gestational age when maternal illness began. Even when in utero infection has resolved before delivery, these infants remain at risk for delayed complications such as SSPE.

Acute management, however, follows 2 tracks. Neonates of any gestational age born after maternal symptom onset through 14 days after maternal rash onset should be considered at risk for symptomatic, transmissible infection. That window combines the longest reported interval between maternal and neonatal rash onset after in utero exposure (10 days) with an additional 4-day presumed infectious period in case the neonate developed congenital measles before birth and remained infectious at delivery. For this group, the AAP calls for diagnostic testing, consideration of immune globulin, supportive care, isolation, and parent-neonate separation when indicated.

The guidance also notes that if a nonimmune pregnant person delivers shortly after a documented measles exposure but before prodromal symptoms begin, in utero exposure is theoretically possible because a low-level primary viremia occurs soon after exposure. However, no case reports suggest vertical transmission during primary viremia; transmission generally occurs during the secondary, high-level viremia that coincides with symptom onset.

What testing is recommended for neonates born within 14 days of maternal rash?

Neonates born after maternal prodromal symptom onset through 14 days after maternal rash onset should be tested for measles. Reverse transcriptase-polymerase chain reaction (RT-PCR) is suggested as the most sensitive and specific test and can be run on respiratory (nasopharyngeal or oropharyngeal/throat swab) or urine specimens. Respiratory swabs are preferred because viral burden is higher at those sites. RT-PCR on blood or placenta is limited to research settings.

Measles immunoglobulin (Ig) M testing may also be considered. Because IgM does not cross the placenta, its detection in a neonate suggests infection, and immune globulin intramuscular (IGIM) and immune globulin intravenous (IGIV) products contain too little IgM to interfere with results. Both false-positive and false-negative IgM results can occur.

Negative IgM or RT-PCR results in an asymptomatic neonate do not fully exclude in utero transmission; in some cases, early negative results have been followed by positive ones. Testing should be repeated if signs or symptoms of acute measles develop during monitoring. For neonates who test negative and remain asymptomatic, repeat testing on day 10 of life may be considered, recognizing that a positive result may not change management and a negative result may not rule out transmission. For neonates with positive RT-PCR results, serial testing (eg, weekly) may help guide disposition and ongoing precautions in high-risk settings such as the neonatal intensive care unit (NICU).

When should neonates receive immune globulin, and which formulation is preferred?

All neonates born within 14 days of maternal rash onset should be considered for immune globulin, which may prevent overt symptomatic congenital measles and may limit morbidity and mortality in those who develop it.

For neonates without overt signs or symptoms at birth, immune globulin should be given as soon as possible. Case reports suggest that IGIM or IGIV given at or shortly after birth may attenuate or prevent symptoms in asymptomatic neonates born to a parent with acute measles. It may also protect against postnatal infection if birth occurs during the maternal infectious period.

Management of neonates born with symptomatic measles is less certain. Immune globulin is expected to be most effective during the incubation period rather than during acute infection. Still, it has been given to some neonates with a measles rash at birth without noted adverse effects, and the immaturity of the neonatal immune system suggests it could have a role in preventing measles morbidity.

IGIM is generally the preferred formulation for exposed infants younger than 12 months, at a dose of 0.5 mL/kg (maximum 15 mL). However, there is no specific guidance on the preferred route for neonates born to a parent with acute measles, and the choice between IGIM and IGIV may depend on product availability, intravenous access, and birth weight, which can affect the muscle mass available for intramuscular injection.

What supportive care, including vitamin A, is recommended?

Neonates with congenital measles should be monitored closely and managed supportively based on their clinical presentation. Those with confirmed congenital measles, particularly with overt symptoms, should receive vitamin A at 50,000 IU (15,000 μg RAE) once daily for 2 days unless a contraindication, such as severe liver disease, is present. The role of vitamin A in neonates who test RT-PCR positive but lack overt measles-like symptoms is unclear.

How long should neonates born within 14 days of maternal rash stay in airborne isolation?

Neonates of any gestational age born within 14 days of maternal rash onset should be delivered and managed in airborne isolation until their infectiousness can be assessed.

For neonates born with a measles rash or other signs of acute measles, airborne precautions should continue until the neonate is no longer considered infectious. Term neonates appear more likely to have a typical measles course, so the standard infectious period through 4 days after rash onset may be reasonable, although data are lacking and local circumstances may warrant longer isolation. Preterm neonates may require a different approach given uncertainty about the infectious period with immune immaturity, especially during prolonged NICU stays. Prolonged RT-PCR detection of measles virus has been reported, particularly in preterm neonates.

Because data on isolation duration for preterm neonates and for neonates with congenital measles but no rash are limited, the AAP advises case-by-case discussion with public health authorities, infection prevention specialists, and clinicians, weighing gestational age, other congenital conditions, disease severity, and facility capacity. Facilities could extend airborne isolation for the duration of illness, as recommended for immunocompromised patients in CDC interim infection prevention and control recommendations for measles in health care settings. Another reasonable option is to discontinue precautions after 2 consecutive negative RT-PCR results, with testing frequency and timing based on capacity and turnaround time.

For neonates born without signs of measles, airborne precautions and symptom monitoring should continue through at least 14 days after maternal rash onset. If birth occurs during the maternal infectious period (4 days before through 4 days after rash onset), postnatal exposure is also possible, and precautions should be maintained for the standard 21-day period after respiratory exposure. For neonates exposed postnatally, receipt of immune globulin extends quarantine and monitoring to 28 days from birth.

Whether immune globulin lengthens the incubation period for measles acquired only in utero is unknown. Published reports suggest neonatal rash appeared within 8 days of maternal rash onset regardless of immune globulin receipt, so it is unclear whether monitoring and empiric isolation should be extended in that scenario. Potentially exposed household members should be carefully screened before visiting.

Should the birth parent and neonate be separated?

Data to guide this decision are limited. When an asymptomatic neonate is born during the maternal infectious period, it may be unclear for a time whether in utero transmission occurred, while postnatal transmission remains preventable. The high contagiousness of measles and the potential severity of neonatal infection should be weighed in consultation with the facility infection preventionist and the family. The AAP recommends that parents with infections requiring airborne precautions avoid contact with the infant, although the infant can be fed the parent's expressed human milk.

If the dyad is not separated during the parent's infectious period, the parent should be placed in an airborne infection isolation room with 20 or more air changes per hour. The parent may consider source control, such as a NIOSH-approved disposable N95 respirator without an exhaust valve, although no data are available to support this practice. Human milk remains a safe feeding option.

No separation is recommended if the neonate is born after the maternal infectious period.

How should neonates born more than 14 days after maternal rash be managed?

Neonates born at or after 34 weeks' gestation more than 14 days after maternal rash onset are generally not expected to be at risk for transmissible acute measles after birth. In utero infection may have occurred, but the neonate would not be anticipated to be infectious at delivery, and high levels of maternal IgG transferred during convalescence should help suppress viral replication, unless a maternal condition such as uncontrolled HIV limits placental antibody transfer. Testing, isolation, and immune globulin may therefore not be needed or beneficial.

The value of testing in this group is unclear, although some experts recommend testing asymptomatic neonates after maternal measles at any point in pregnancy given the risk of late complications and potential infection control implications of detecting viral RNA. Immune globulin is usually unnecessary because the window for attenuating congenital infection has passed and maternal IgG has already crossed the placenta. It should be considered if the infant has a new exposure, such as another infected household contact, or if the birth parent has a condition that would prolong viral shedding.

Empiric airborne precautions until measles testing is negative are recommended for neonates who are born preterm, admitted to settings with highly susceptible hosts such as the NICU or newborn nursery (regardless of gestational age), or born to a parent with a condition that limits placental antibody transfer. For term or near-term neonates rooming in with the parent, standard precautions may be considered, although some infection preventionists may recommend airborne precautions in any inpatient setting.

The guidance notes that IgG transfer before 32 weeks' gestation is more variable, with fetal concentrations reaching 50% of maternal levels by 32 to 34 weeks. In a French case series, measles was detected by RT-PCR in the saliva of a neonate born at 40 weeks after maternal measles at 19 weeks, and in the placenta after delivery at 41 weeks following maternal measles at 33 weeks. Viral viability was not assessed; no neonates in the series were symptomatic at birth, and fetal infection had likely resolved by delivery. The AAP notes that data on viral shedding and viability in neonates are still needed.

What long-term follow-up do exposed infants need?

Neonates exposed to measles in utero at any gestational age, including those who appear well at birth, may be at higher risk for delayed sequelae such as encephalitis and SSPE than people infected later in life. The latency period may be as short as months to a few years, and neurologic decline may begin rapidly.

For infants and children with known congenital measles or known in utero exposure, the guidance calls for long-term follow-up with vigilance for neurologic and immunologic complications. Parents should be carefully counseled, and clinicians should watch for seizures, regression in milestones, and, in older children, academic difficulties that could signal early SSPE. No intervention has been proven to improve neurologic outcomes, although antiviral and immunomodulatory treatments have been attempted.

How can congenital measles be prevented?

Measles, mumps, and rubella (MMR) vaccination before pregnancy to establish maternal immunity is the best prevention. Measles-containing vaccine should not be given to people known to be pregnant. Susceptible pregnant people exposed to measles should receive postexposure prophylaxis with IGIV, and exposed neonates should receive either IGIV or IGIM.

Reference

1. American Academy of Pediatrics. Congenital measles: frequently asked questions. Red Book Online. Published September 8, 2026. Accessed October 28, 2026. https://publications.aap.org/redbook/resources/35976